Do sex differences exist in Fuchs endothelial corneal dystrophy?

Yes, Significant Sex Differences Exist in Fuchs Endothelial Corneal Dystrophy

Women are disproportionately affected by Fuchs dystrophy, experiencing both higher disease prevalence and more severe clinical manifestations, with important implications for screening, counseling, and surgical planning.

Epidemiology and Disease Prevalence

The sex disparity in Fuchs endothelial corneal dystrophy (FECD) is well-established across multiple lines of evidence. Historical pathology reviews demonstrate a marked female predominance, with women comprising the majority of patients requiring penetrating keratoplasty for FECD 1. While early studies suggested this might reflect ascertainment bias, more recent genetic and molecular investigations confirm genuine biological differences.

Key epidemiological findings:

• Female sex increases odds of developing advanced FECD (grades 4-6) by 34% 2
• Women demonstrate generally increased disease severity compared to men 1
• The disease shows autosomal-dominant inheritance with high penetrance but variable expressivity that is more pronounced in females 1

Molecular and Genetic Mechanisms

Recent research has identified specific biological mechanisms explaining the female predominance:

Estrogen metabolism plays a central pathogenic role 3, 4. The key enzyme NQO1, which neutralizes reactive estrogen metabolites, is downregulated in FECD. This deficiency renders corneal endothelial cells susceptible to:

• Formation of genotoxic estrogen-DNA adducts
• Increased macromolecular DNA damage
• Enhanced oxidative stress from catechol estrogen (4-OHE2) byproducts

Environmental factors interact with sex-specific biology. UVA light exposure induces greater corneal endothelial cell loss in females through activation of estrogen-metabolizing enzyme CYP1B1, leading to reactive estrogen metabolite formation and estrogen-DNA adducts specifically in female mice 4. This provides a mechanistic link between environmental triggers and the female predominance observed clinically.

Gene expression analysis reveals distinct sex-dependent patterns 5. In FECD patients, 309 differentially expressed genes were identified between sexes, with upregulated genes in females associated with immune responses and downregulated genes linked to peptide hormone binding.

Clinical Manifestations and Outcomes

The sex differences extend beyond prevalence to clinical presentation and outcomes:

Corneal thickness patterns differ by sex:

• Female sex is associated with decreased average central corneal thickness by 6.9 μm in general populations 2
• However, women with FECD are much more likely to develop thin corneas post-DMEK (40% of women vs. 3.6% of men with CCT below 500 μm) 6
• Women show greater percentage pachymetric reduction following DMEK, suggesting more pronounced stromal remodeling 6

Protective role of ovarian hormones: Paradoxically, while estrogen metabolites contribute to disease pathogenesis, ovarian hormones appear protective in maintaining corneal deturgescence. Evidence from congenital hereditary endothelial dystrophy (CHED) models shows that gonadectomy in females increases corneal edema, suggesting estrogens promote alternative energy metabolism pathways that reduce oxidative stress 7.

Clinical Implications and Risk Stratification

For screening and counseling:

• Women with family history of FECD warrant earlier and more frequent screening
• Female patients should receive specific counseling about their elevated risk for advanced disease
• Smoking compounds the sex-related risk, increasing odds of advanced FECD by 30% 2

For surgical planning:

• Anticipate greater corneal thinning in women following DMEK, particularly in those with thicker preoperative corneas
• Women may require different postoperative monitoring protocols given their distinct tomographic patterns
• Consider sex-specific differences when counseling about surgical outcomes

Common pitfall: Do not assume male patients are unaffected or at low risk. While women show higher prevalence and severity, men with FECD still require appropriate evaluation and management. The sex difference represents a relative rather than absolute distinction.

The convergence of genetic, molecular, and clinical evidence establishes that sex differences in FECD are fundamental to disease biology rather than artifacts of ascertainment or reporting bias. Recognition of these differences should inform clinical practice, particularly regarding screening intensity, patient counseling, and anticipation of postoperative outcomes.